| Literature DB >> 23197020 |
Ernest C Borden1, Afshin Dowlati.
Abstract
As cancer therapy progresses through the development of molecularly targeted drugs, the focus of Phase I trials needs to shift towards investigating end points that could guide more effective trial design, dosing and choice of tumour setting for Phase II studies.Entities:
Mesh：
Substances：
Year: 2012 PMID： 23197020 DOI： 10.1038/nrd3909
Source DB: PubMed Journal: Nat Rev Drug Discov ISSN： 1474-1776 Impact factor: 84.694